CF
MACK

Centaurus Financial’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Centaurus Financial’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-3
Closed – – 2455
2018
Q2 		$0 Buy
+3
New +$20 ﹤0.01% 2497

Other funds holding MACK

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
WIM
Wittenberg Investment Management Carlisle, Massachusetts $269M AUM 28.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Centaurus Financial's MACK Position: Q3 2018 in Review

Centaurus Financial sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q3 2018, closing a stake of 3 shares.

Centaurus Financial first reported a position in MACK in Q2 2018 and held it in 1 quarter. The position peaked at $0 in Q2 2018. 63 funds tracked by Wall St. Rank hold MACK as of Q3 2018.

  • Centaurus Financial reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q3 2018 after selling out during the quarter.
  • Centaurus Financial sold 3 Merrimack Pharmaceuticals, Inc. shares in Q3 2018.
  • Centaurus Financial first reported a position in Merrimack Pharmaceuticals, Inc. in Q2 2018 and held it in 1 quarter.
  • Centaurus Financial's Merrimack Pharmaceuticals, Inc. position peaked at $0 in Q2 2018.
  • 63 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q3 2018.

Based on Centaurus Financial's 13F filing for Q3 2018, filed 5 Nov 2018.